Core Points - Windtree Therapeutics, Inc. has announced a 1-for-50 reverse stock split approved by its board of directors and stockholders to comply with Nasdaq's minimum bid price requirement [1][2] - The reverse stock split will take effect on February 20, 2025, and trading on a reverse-adjusted basis will begin on February 21, 2025 [2] - Post-split, the number of outstanding shares will be reduced to approximately 700,000, with no fractional shares issued [4] Company Overview - Windtree Therapeutics is a biotechnology company focused on developing innovative therapies for critical conditions and diseases, including a Phase 2 candidate for acute heart failure [7] - The company has a licensing business model with existing partnership out-licenses [7]
Windtree Therapeutics, Inc. Announces Reverse Stock Split